MCL1 and acute myeloid leukemia: We discovered that several targeted compounds had reduced efficacy in AML cells grown on HS-5 stroma, while the MCL1 inhibitor S63845 induced cell death with equal efficacy in the absence or presence of bone marrow stroma, making it an excellent candidate to target leukemic stem cells in the bone marrow.